Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$7.1B
69M shares
52-week range
$74.50 – $122.20
47% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
27.7
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
www.rhythmtx.comNo one on the platform currently holds RYTM.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 258,011 | $22.4M |
No one on the platform has traded RYTM yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 45.8% | |||||
| Profit Margin % | -103.6% | -703.1% | ||||
| Free Cash Flow Margin % | -61.5% | -1175.6% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $312M | +65.3% | $-3.03 | $-3.32–$-2.69 | — | 10 |
| 2027 | $555M | +77.5% | $-0.66 | $-1.59–$0.22 | — | 10 |
| 2028 | $868M | +56.5% | $2.34 | $0.28–$4.38 | 41.4× | 10 |
| 2029 | $1.3B | +46.2% | $6.41 | $5.26–$7.85 | 15.1× | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $-0.81 | $-0.73 | +9.6% |
| 2026-05-05 | $-0.86 | $-0.83 | +3.5% |
| 2026-02-26 | $-0.79 | $-0.73 | +7.6% |
| 2025-11-04 | $-0.72 | $-0.82 | -13.9% |
| 2025-08-05 | $-0.66 | $-0.75 | -13.6% |
| 2025-05-07 | $-0.69 | $-0.81 | -17.4% |
| 2025-02-26 | $-0.69 | $-0.72 | -4.3% |
| 2024-11-05 | $-0.80 |
| $-0.73 |
| +8.8% |
| $113M |
| — |
| CGEMCullinan Therapeutics, Inc. | $20.54 | +0.69% | $1.3B | — |
| INZYInozyme Pharma, Inc. | $4.00 | +0.25% | $258M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$PTN GLP-1s Transformed Obesity. Billions Are Now Moving Into Rare Diseases That Require a Different Approach. $RYTM $LLY $VKTX https://www.benzinga.com/content/61786779/glp-1s-transformed-obesity-billions-are-now-moving-rare-diseases-require-different-approach
View on StockTwits ↗
$RYTM Been in this since $6. Stalled a bit here but it will head higher.
View on StockTwits ↗
$RYTM — ESPE 2026 data drop: French early-access study (n=30, ages 6-17, acquired hypothalamic obesity) shows setmelanotide BMI reduction of 11.5% at 6mo, 13.4% at 9mo, 10.5% at 12mo, 9.0% at 18mo. 88%+ hit ≥0.2-point BMI z-score reduction; no new safety signals. Separate Phase 3 TRANSCEND post-hoc: setmelanotide beat placebo on multiple cardiometabolic measures (visceral fat, triglycerides, fatty liver risk). Caveat: post-hoc analysis, not a new primary endpoint; longest follow-up cohorts are thin (n=13, n=5). Watch payer coverage and physician uptake next. $RYTM #Biotech #WeightLoss https://prismmarketview.com/rhythm-highlights-setmelanotide-benefits-in-pediatric-hypothalamic-obesity-studies/
View on StockTwits ↗$RYTM May head lower but adding to position today.
View on StockTwits ↗
Guggenheim⬆️ $AMLX's PT to $57 (from $55 prior) due to⬆️avexitide PoS (95% from 90% prior)—sees significant⬆️pot'l to its valuation. $RYTM $ASND MBX VOGX RICFY ZLDPF ZLDPY RZLT Here's what Guggenheim said: https://x.com/Quantumup1/status/2092944835665650096?s=20
View on StockTwits ↗
$RYTM the street can only run for so long, and then it’s going to have to submit to the power of rhythm! 
View on StockTwits ↗$PTN $RYTM We know it’s crazy to think that because you’re the only one that does. Cray cray.
View on StockTwits ↗
$PTN $RYTM Congrats to Rhythm on HO drug approval in Japan… another 8K patients expanding the addressable mkt oppty so the case for upside beyond the current already ~$8BN mkt cap continues! Crazy to think market may eventually come around to PTN having a best in class asset for HO when we get cars turn in 1H 2027 following IND filing coming soon (Q4 2026) so just about a month away. Again, upside case here is simple $18M mkt cap vs $8BN… how does that make sense once PTN officially hits clin stage this Q4… Get that IND filed Palatin, come on can’t wait!! https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-mhlw-approval-imcivreer
View on StockTwits ↗$RYTM Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- let’s gooooooo! Hopefully this starts moving us upward tomorrow! 
View on StockTwits ↗$PTN keep an eye on this one! Been a painful newsflow vacuum but we now approaching potential catalyst rich setup again so I think the SP can recover lost ground and quickly as interest grows again. Most immediately we saw smart HC specialists buy in per 13Fs including new positions albeit small from woodline and Opaleye and big boys Janus, logos, augc, RA, Sirenia all still top holders. Next reporting is September and November I believe and all important opening of the IND which they guided to filing in Q4 so that could happen as soon as October. Meanwhile $RYTM trades at $7.5-$8B on strong commercial momentum from older gen Mc4r asset with daily dosing burden. Once PTN files for their differentiated once weekly version w even better pot’l tolerability profile… I think new funds jump in as PTN officially be 30 days out from being ckincical stage company… then the investment case is really simple: hey $SLNO bot for $3B/ this is potential mini RYTM so valuation gap should close! GLTA
View on StockTwits ↗
If it is then this should be the 🎁 in $HRMY N FRYday da 🧠 gets back in $RYTM
View on StockTwits ↗da huckleberries are below da $$$$ and soon da 🧠 shud be back in $RYTM out of the tightness if only they gave YO a sign in $HRMY while da 🐑 are Semi worried about AI stonks that 🐑 term stink.
View on StockTwits ↗
$AMLX $VKTX rip off. Look at $RYTM drug price Welcome to the woke health system
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.